<DOC>
	<DOCNO>NCT00211887</DOCNO>
	<brief_summary>This randomize clinical trial ( RCT ) determine combine use interferon beta-1a ( IFN ) glatiramer acetate ( GA ) measurably well therapy either agent use individually patient relapsing-remitting ( RR ) multiple sclerosis ( MS ) .</brief_summary>
	<brief_title>Combination Therapy Patients With Relapsing-Remitting Multiple Sclerosis ( MS ) CombiRx</brief_title>
	<detailed_description>This multicenter , double blind , randomize trial examine combination therapy versus single agent therapy three-year follow-up last patient randomize . All patient remain therapy last patient completes study . All patient transition , base finding , open label combination continue follow-up recommendation single agent therapy . While study design benefit two arm single agent therapy examine important question whether difference single agent , primary interest combination therapy . Therefore , two-group combination versus single agent concept use - split population single agent combination therapy equally . The single agent arm divide two group , IFN GA provide 3 treatment arm : IFN intramuscularly ( IM ) GA subcutaneously ( SC ) ( 50 % patient ) , IFN IM placebo SC ( 25 % patient ) GA SC placebo IM ( 25 % patient ) .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<mesh_term>Glatiramer Acetate</mesh_term>
	<criteria>Male female subject age 18 60 year , inclusive . Diagnosis relapsingremitting MS either Poser McDonald criterion . Expanded Disability Status Scale ( EDSS ) score 0 5.5 , inclusive . At least 2 exacerbation prior three year ; one exacerbation may utilize McDonald MRI criterion dissemination time ( new gadolinium [ Gd ] enhance lesion demonstrate scan do least 3 month follow onset clinical attack new T2 lesion Gdenhancing lesion followup scan additional 3 month ) . Give write informed consent prior test protocol , include screen test evaluation consider part subject 's routine care . Any prior use interferon beta glatiramer acetate . Acute exacerbation within 30 day screen . Steroids acute exacerbation ( &gt; 100 mg/day ) within 30 day study entrance chronic systemic steroid use . Evidence progressive MS. Use IVIg , azathioprine , methotrexate , cyclosporine , mitoxantrone , cyclophosphamide , mycophenolate ( CellCept ) plasma exchange twelve week prior study drug dosing . Any previous treatment natalizumab ( Tysabri , Antegren ) , cladribine , T cell vaccine , Campath , daclizumab , rituximab , alter peptide ligand total lymphoid irradiation . Treatment 4 aminopyridines four week prior study drug dosing . Prior treatment investigational drug , unless approve Clinical Coordinating Center ( Dr. Lublin ) . Inability perform baseline MSFC ( time 25foot walk , 9hole peg test [ 9HPT ] , Paced Auditory Serial Addition Test 3 [ PASAT3 ] ) . Inability undergo baseline MRI scan . History significant cardiac , hepatic , pulmonary , renal disease , immune deficiency , medical condition would preclude therapy interferon beta , glatiramer acetate , participation study . Known history sensitivity gadopentetate dimeglumine mannitol . History seizure within 3 month prior randomization . History suicidal ideation episode severe depression within 3 month prior randomization . Abnormal screen blood test exceed limit define : Alanine transaminase ( ALT ) aspartate transaminase ( AST ) great two time upper limit normal ( i.e. , &gt; 2 × ULN ) Total white blood cell count &lt; 2,300/mm3 Platelet count &lt; 80,000/mm3 Creatinine &gt; 2 × ULN Participation another experimental clinical trial , without formal approval . History alcohol drug abuse within 2 year prior randomization . Female subject currently pregnant , breastfeed , plan become pregnant . For female subject , unless postmenopausal surgically sterile , unwillingness practice effective contraception , define investigator , study . The rhythm method use sole method contraception . Unwillingness inability comply requirement protocol include presence condition likely affect subject 's returning schedule followup visit schedule ( physical , mental , social condition ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>Clinical trial</keyword>
	<keyword>treatment trial</keyword>
	<keyword>autoimmune disease</keyword>
	<keyword>Relapsing Remitting</keyword>
	<keyword>MS Treatment</keyword>
	<keyword>interferon beta-1a</keyword>
	<keyword>glatiramer acetate</keyword>
</DOC>